NLRP3 and triple-A syndrome: The vascular endogenous bioactive peptide intermedin (IMD) inhibits the Notch1 signaling pathway, preventing NLRP3 (NOD‐, LRR‐, and pyrin domain‐containing protein 3) activation and M1 polarization, and promoting M2 macrophage polarization, thereby reducing local aortic inflammation and preventing AAA formation.37